High-Throughput Crystallography and Its Applications in Drug Discovery

Herbert Nar(Boehringer Ingelheim (Germany)), D.J. Reinert(Boehringer Ingelheim (Germany)), Stefan Hörer(Boehringer Ingelheim (Germany)), Dennis Fiegen(Boehringer Ingelheim (Germany)), Alexander Pautsch(Boehringer Ingelheim (Germany))

Elsevier eBooks

September 27, 2016

10.1016/b978-0-12-409547-2.12317-0

Cited by 0

Related Papers

A specific antidote for dabigatran: functional and structural characterization

|Blood|2013|562

Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0

|Journal of Molecular Biology|1991|487

Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors

|Journal of Medicinal Chemistry|2002|454

Biophysics in drug discovery: impact, challenges and opportunities

|Nature Reviews Drug Discovery|2016|383

8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

|Journal of Medicinal Chemistry|2007|285